Inclusion Criteria:

Patients with acute or chronic leukemia or advanced Hodgkin or non Hodgkin lymphoma or myelodsyplastic/myeloproliferative disease who are unlikely to be cured by standard chemotherapy treatments. This includes patients who have relapsed after standard chemotherapy treatments and patients in first remission with unfavorable prognostic features.

Patient must have a genotype HLA identical stem cell donor.

Exclusion Criteria:

Patients with a life expectancy (less than or equal to 6 weeks) limited by disease other than leukemia.

Patients with symptomatic cardiac failure unrelieved by medical therapy or evidence of significant cardiac dysfunction by echocardiogram (shortening fraction <20%).

Patients with severe renal disease (i.e., creatinine greater than 3 times normal for age).

Patients with pre-existing severe restrictive pulmonary disease (FVC less than 40% of predicted).

Patients with severe hepatic disease (direct bilirubin greater than 3 mg/dl or AST greater than 500 IU/L).

Patients with severe personality disorder or mental illness.

Patients with severe infection that in the estimation of the principal investigator prohibits the use of ablative chemotherapy.

Patients who are documented HIV positive.

Patients with a Karnofsky performance score <60% or Lansky performance score <50%.

NOTE: Patients who would be excluded from treatment on this protocol strictly for laboratory or performance abnormalities can be included at the principal investigator's discretion after consultation with the members of the SCT Policy and Procedures Committee.